Navigation Links
Alzheimer's Growth Shows Need for Increased FDA Funding

Coalition for a Stronger FDA says drug review programs need more money

WASHINGTON, March 21, 2007 /PRNewswire-USNewswire/ -- A new estimate by the Alzheimer's Association shows that more than five million Americans are living with Alzheimer's disease -- a 10 percent growth over previous estimates and a number that could more than triple in the coming decades unless new treatments and cures are developed for the debilitating illness.

The new numbers re-emphasize the need for a strong and adequately funded drug safety review program at the Food and Drug Administration to ensure that new Alzheimer's disease drugs can be safely and rapidly brought to market, according to the Coalition for a Stronger FDA.

"As the population ages, more and more American families will be touched by Alzheimer's disease," said Tommy G. Thompson, co-chairman of the Coalition and the former Secretary of the Department of Health and Human Services. "We simply can't afford for the FDA to be a bottleneck for new drugs and treatments because it is not adequately funded."

The Alzheimer's Association estimates that without a cure or effective treatments to delay the onset or progression of Alzheimer's disease, the prevalence could soar to 7.7 million people with the disease by 2030 and 16 million by the middle of the century. More information on the Alzheimer's Association report can be found at

"The funds needed by the FDA will be repaid hundreds of times over in health care savings by getting new Alzheimer's disease drugs quickly and safely to market," said Stephen McConnell of the Alzheimer's Association, a member of the Coalition. "It's an investment we can't afford not to make."

"We are committed to delivering transformational therapies to Alzheimer's patients within the next decade," said Daniel Perry of Accelerate Cure- Treatment for Alzheimer's disease, a member of the Coalition. "A lack of sufficient FDA appropriations stands in the way of delivering treatments that could lessen the human and economic tolls that Alzheimer's exacts on patients and their loved ones."

The Coalition for a Stronger FDA -- a diverse group of consumer, non- profit, patient and industry groups -- is committed to working with Congress and the administration to give the FDA the resources it needs to fulfill its mission. As part of a five-year process to significantly expand the agency's budget, the Coalition is seeking $175 million in increases for 2008 over the fiscal year 2007 budget, including $40 million for drug review programs, $115 million for food safety programs and $20 million for medical device programs.

The increases will allow the FDA to build confidence in the public health system, speed innovation in medical technology, ensure the United States remains competitive in foreign markets, and boosts public confidence in the agency and its mission.

Specifically, a $40 million increase in the drug budget in 2008 would allow the FDA to provide faster and safer approval of products that are saving lives and transforming health care; promote new drug technologies that will revolutionize pharmaceutical therapies and ensure continued U.S. leadership in drug innovation; enhance the surveillance capability over new drugs once they reach the market; and further integrate emerging science into the regulatory process.

About the Coalition

The Coalition for a Stronger FDA is designed to be a multi-year effort with the following goals: (1) making sure the FDA has sufficient resources to protect patients and consumers and (2) maintaining public confidence and trust in the FDA. Tommy G. Thompson, Donna E. Shalala and Dr. Louis Sullivan -- the last three Secretaries of the Department of Health and Human Services -- are the co-chairs of the Coalition. Member organizations of the Coalition include patient groups, consumer advocates, public health organizations and innovative companies. A list of members and more information on the Coalition can be found at

CONTACT: Tony Jewell, +1-202-530-4510, for Coalition for a Stronger FDA

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
7. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
8. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
9. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
10. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
11. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... -- --> --> ... das Patent über eine neue Hepatitis-B-Behandlung, welches sie gemeinsam ... Enyo Pharma vergeben haben. Im Rahmen ... von Edelris gemeinsam mit seinen Partnern Inserm und Poxel ... identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die zu ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Beddit® has launched ... Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that rates ... how well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):